# AstraZeneca suffers another setback as it halts volrustomig lung cancer trial

> **Newsylist Open Intelligence Dossier** · First detected: 2026-08-17 13:29 UTC · Category: Business · Sources: 1 · Current Velocity: 0.25

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Fierce Biotech | AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda | 2026-08-17 06:28 | [Source Link](https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc0lEbGlDQ3JtSEVqMjMxN0ZyWG4xN0NIQ1k1bEItb0NKZ2wybmZrazdjQXVtT1FkVnV3TjdpakVxYWo4SWQ1VkpfMDZKd2ZjeVlxSkdkMWk3VDM3d1A5alpDVmJCZmMxWVZ2d1RpWkd2aFlabWQ2RENFaG1feVVCZF9oazZzTFRaZkN6R1Axd2JmaVBhdk9jRGRuTUI0cGdnUEFJbHBxQWEweDNjV2NsQ2ZVMnY5c2dHTDdLajRyQjlQNGs?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-08-17/astrazeneca-suffers-another-setback-as-it-halts-volrustomig-lung-cancer-trial*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*